Significant Ownership of ELI LILLY & Co
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for ELI LILLY & Co focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager location
- Indianapolis, IN
- Manager signature
- /s/ Christopher Anderson - Christopher Anderson, Vice President, Leader of Corporate Securities and Assistant Corporate Secretary
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow ELI LILLY & Co and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from ELI LILLY & Co
Significant Ownership of ELI LILLY & Co
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| AKTSQ | Aktis Oncology, Inc. | Common Stock, $0.0001 par value per share | 12% | $63,441 | 6,344,114 | Eli Lilly and Company | 12 Jan 2026 | ||
| IMCR | Immunocore Holdings plc | Ordinary Shares | 0% | 0 | ELI LILLY & Co | 30 Sep 2025 |
Schedules 13D/G Reported by ELI LILLY & Co:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.